Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Jose G Monzon; Hatim Karachiwala; John Walker; Rakesh Goel; Paul Wheatley-Price; Timothy R. Asmis; Vishal Navani; Patricia A. Tang; Michael M. Vickers

doi:10.1016/j.ejca.2026.116738

← 뒤로

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

1/5 보강

European journal of cancer (Oxford, England : 1990) 📖 저널 OA 11.1% 2021~2026 2026 Vol.240() p. 116738 OA Cancer Diagnosis and Treatment

OpenAlex 토픽 · Cancer Diagnosis and Treatment Nonmelanoma Skin Cancer Studies Cancer Immunotherapy and Biomarkers

Monzon JG, Karachiwala H, Walker J, Goel R, Wheatley-Price P, Asmis TR

📖 무료 전문 🔓 OA PDF unpaywall · unknown

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Jose G Monzon, Hatim Karachiwala, et al. (2026). Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].. European journal of cancer (Oxford, England : 1990), 240, 116738. https://doi.org/10.1016/j.ejca.2026.116738

MLA Jose G Monzon, et al.. "Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].." European journal of cancer (Oxford, England : 1990), vol. 240, 2026, pp. 116738.

PMID 41997036 ↗

DOI 10.1016/j.ejca.2026.116738

같은 제1저자의 인용 많은 논문 (1)

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.
European journal of cancer (Oxford, England : 1990) 2026